Evidence map›Paper›PMID 38573423›Full record

ArticleDiscover oncology2024

Giant cell tumor of bone at distal radius suffered more soft tissue recurrence and ultrasonography is effective to detect the soft tissue recurrence.

Lukuan Cui, Yang Sun, Tao Jin, Daoyang Fan, Weifeng Liu

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Efficacy of microwaveAmerican journal of translational research · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lukuan CuiDepartment of Bone and Soft Tissue Oncology, Cangzhou Hospital of Integrated TCM-WM·Hebei, No. 5, Xianghai Road, Cangzhou, 061000, Hebei, People's Republic of China.
Yang SunDepartment of Orthopedic Oncology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, No. 31, Xinjiekou East Steet, Xicheng District, Beijing, 100035, People's Republic of China.
Tao JinDepartment of Orthopedic Oncology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, No. 31, Xinjiekou East Steet, Xicheng District, Beijing, 100035, People's Republic of China.
Daoyang FanDepartment of Orthopedic Oncology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, No. 31, Xinjiekou East Steet, Xicheng District, Beijing, 100035, People's Republic of China.
Weifeng LiuDepartment of Orthopedic Oncology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, No. 31, Xinjiekou East Steet, Xicheng District, Beijing, 100035, People's Republic of China. liuweifengjst@126.com.
Peking University · CNCapital Medical University · CNPeople's Hospital of Cangzhou · CN

Funding

Beijing Municipal Health Commission BJRITO-RDP-2023
6 · The paper itself

Abstract

backgroundSoft tissue recurrence of giant cell tumor of bone (GCTB) is rare. This study aims to provide its prevalence, recurrent locations, risk factors, effective detection methods and a modified classification for this recurrence.

methodsPatients with soft tissue recurrence after primary surgery for GCTB were screened from January 2003 to December 2022. General data, recurrence frequency, types according to an original classification (type-I: peripheral ossification; type-II: central ossification; type-III: without ossification), a modified classification with more detailed subtypes (type I-1: ≤ 1/2 peripheral ossification; type I-2: ≥ 1/2 peripheral ossification; type II-1: ≤ 1/2 central ossification; type II-2: ≥ 1/2 central ossification; type III: without ossification), locations, detection methods such as ultrasonography, X-ray, CT or MRI, Musculoskeletal Tumor Society (MSTS) scores were recorded. Multivariate regression analysis was conducted to identify risk factors for recurrence frequency.

resultsA total of 558 recurrent cases were identified from 2009 patients with GCTB. Among them, 32 were soft tissue recurrence. The total recurrence rate was 27.78% (558/2009). Soft tissue recurrence rate was 5.73% among 558 recurrent cases, and 1.59% among 2009 GCTB patients, respectively. After excluding one patient lost to follow-up, 10 males and 21 females with the mean age of 28.52 ± 9.93 (16-57) years were included. The definitive diagnosis of all recurrences was confirmed by postoperative pathology. The interval from primary surgery to the first recurrence was 23.23 ± 26.12 (2-27) months. Eight recurrences occurred from primary GCTB located at distal radius, followed by distal femur (6 cases). Recurrence occurred twice in 12 patients and 3 times in 7 patients. Twenty-seven recurrences were firstly detected by ultrasonography, followed by CT or X-ray (10 cases in each). Types at the first recurrence were 5 cases in type-I, 8 in type-II and 18 in type-III. According to the modified classification, 3 patients in type I-1, 2 in type I-2, 1 in type II-1, 7 in type II-2, and 18 in type III. The mean MSTS score was 26.62 ± 4.21 (14-30). Neither Campanacci grade nor recurrence type, modified classification and other characters, were identified as risk factors.

conclusionsSoft tissue recurrence of GCTB may recur for more than once and distal radius was the most common location of primary GCTB that would suffer a soft tissue recurrence. Ultrasonography was a useful method to detect the recurrence. Since no risk factors were discovered, a careful follow-up with ultrasonography was recommended.

Indexed as

Giant cell tumor of boneRecurrenceRisk factorSoft tissueUltrasonography

Identifiers

PMID38573423
PMCPMC10994907
OpenAlexW4393940270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.